EP1455816A4 - Hla-klasse-i- und -ii-bindende peptide und deren verwendung - Google Patents

Hla-klasse-i- und -ii-bindende peptide und deren verwendung

Info

Publication number
EP1455816A4
EP1455816A4 EP01274676A EP01274676A EP1455816A4 EP 1455816 A4 EP1455816 A4 EP 1455816A4 EP 01274676 A EP01274676 A EP 01274676A EP 01274676 A EP01274676 A EP 01274676A EP 1455816 A4 EP1455816 A4 EP 1455816A4
Authority
EP
European Patent Office
Prior art keywords
hla class
binding peptides
peptides
immunogenic
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01274676A
Other languages
English (en)
French (fr)
Other versions
EP1455816A2 (de
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmexa Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to EP07023116A priority Critical patent/EP1911461B1/de
Publication of EP1455816A2 publication Critical patent/EP1455816A2/de
Publication of EP1455816A4 publication Critical patent/EP1455816A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP01274676A 2000-10-19 2001-10-18 Hla-klasse-i- und -ii-bindende peptide und deren verwendung Withdrawn EP1455816A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07023116A EP1911461B1 (de) 2000-10-19 2001-10-18 HLA-Klasse-I- und -Klasse-II-bindende Peptide und ihre Verwendungen

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24235000P 2000-10-19 2000-10-19
US242350P 2000-10-19
US28562401P 2001-04-20 2001-04-20
US285624P 2001-04-20
PCT/US2001/051650 WO2003040165A2 (en) 2000-10-19 2001-10-18 Hla class i and ii binding peptides and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07023116A Division EP1911461B1 (de) 2000-10-19 2001-10-18 HLA-Klasse-I- und -Klasse-II-bindende Peptide und ihre Verwendungen

Publications (2)

Publication Number Publication Date
EP1455816A2 EP1455816A2 (de) 2004-09-15
EP1455816A4 true EP1455816A4 (de) 2007-03-28

Family

ID=26935024

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01274676A Withdrawn EP1455816A4 (de) 2000-10-19 2001-10-18 Hla-klasse-i- und -ii-bindende peptide und deren verwendung
EP07023116A Expired - Lifetime EP1911461B1 (de) 2000-10-19 2001-10-18 HLA-Klasse-I- und -Klasse-II-bindende Peptide und ihre Verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07023116A Expired - Lifetime EP1911461B1 (de) 2000-10-19 2001-10-18 HLA-Klasse-I- und -Klasse-II-bindende Peptide und ihre Verwendungen

Country Status (5)

Country Link
EP (2) EP1455816A4 (de)
AT (1) ATE536187T1 (de)
AU (1) AU2001298049A1 (de)
CA (1) CA2425648A1 (de)
WO (1) WO2003040165A2 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430896A1 (en) * 2000-12-13 2002-06-20 Argonex Pharmaceuticals, Inc. Mhc class i associated peptides for prevention and treatment of tuberculosis
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
IL157772A (en) * 2003-09-04 2016-06-30 Bmr Solutions Ltd Compounds containing oligopeptide derived from turtle larvae and their use to encourage mammalian hemophysis
WO2005037855A2 (en) * 2003-10-17 2005-04-28 Pecos Labs, Inc. T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
GB0406054D0 (en) * 2004-03-17 2004-04-21 Univ Nottingham Trent Prostatic acid phosphatase antigens
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US20080249283A1 (en) * 2004-04-30 2008-10-09 Tomoya Miyakawa Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide Sequences
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1709971A1 (de) * 2005-04-06 2006-10-11 Ganymed Pharmaceuticals AG Peptidantigene zur Verwendung in Prophylaxe, Behandlung und Diagnose von Poxvirusinfektionen
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
BRPI0504117A (pt) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
ATE461216T1 (de) * 2006-01-25 2010-04-15 Viro Pharmaceuticals Gmbh & Co Humaner verstärker der viralen infektion (sevi) und seine anwendung
KR100859972B1 (ko) * 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
EP1840133A1 (de) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. Neue immunomodulierende Oligopeptide
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
KR101543622B1 (ko) 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
PL2227486T3 (pl) * 2007-11-20 2017-09-29 Vianex S.A. Analogi peptydowe i ich koniugaty
US20110207673A1 (en) * 2007-11-20 2011-08-25 Ashutosh Chilkoti Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
US9163077B2 (en) * 2007-12-19 2015-10-20 Rhovac Aps RhoC-based immunotherapy
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US8975086B2 (en) 2008-08-28 2015-03-10 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the DEPDC1 polypeptide
WO2010041241A2 (en) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hiv-1 integrase derived peptides and compositions
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
JP5317336B2 (ja) * 2009-02-23 2013-10-16 国立大学法人東北大学 質量分析装置を用いたタンパク質定量のための評価用ペプチド、人工標準タンパク質、及びタンパク質の定量方法
JP5756792B2 (ja) * 2009-04-02 2015-07-29 ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ 免疫療法のための潜在性ｈｌａ−ａ２４エピトープの同定、最適化及び使用
US8431530B2 (en) 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
WO2011073215A2 (en) * 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
ES2805047T3 (es) 2014-05-09 2021-02-10 Univ Southampton Activación de células NK inducida por péptidos
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
LT3388075T (lt) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11155585B2 (en) 2015-07-09 2021-10-26 Intervacc Ab Vaccine against S. suis infection
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CA2994929A1 (en) 2015-08-12 2017-02-16 Oncotherapy Science, Inc. Depdc1-derived peptide and vaccine containing same
SG11201802286PA (en) 2015-10-08 2018-04-27 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
EP3535284B1 (de) * 2016-11-07 2021-04-21 The United States of America as represented by The Secretary Department of Health and Human Services Entwicklung von agonistenepitopen des humanen papillomavirus
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CA3058807A1 (en) * 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
EP3788343B1 (de) 2018-04-30 2024-03-27 Duke University Auf stimuli reagierende plattform zur abgabe von auf peg-like-polymer basierendem arzneimittel
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US12594347B2 (en) 2018-09-07 2026-04-07 Duke University Nanoparticulate drug delivery systems
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021016534A2 (en) * 2019-07-24 2021-01-28 Agenus Inc. Antigenic polypeptides and methods of use thereof
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
JP2025508970A (ja) * 2022-03-02 2025-04-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｌａ－ａ＊０２：０１制限ヒト前立腺酸性ホスファターゼ（ｐａｐ）エピトープとの反応性を示すヒトｔ細胞受容体対
CN117285597B (zh) * 2023-11-27 2024-01-26 中国科学院烟台海岸带研究所 一种具有降尿酸功能的五肽kk5及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027954A2 (fr) * 1997-12-03 1999-06-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US6019974A (en) 1996-01-26 2000-02-01 Emory University SPE-4 peptides
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US6128946A (en) 1997-06-26 2000-10-10 Crane Nuclear, Inc. Method and apparatus for on-line detection of leaky emergency shut down or other valves
WO2001021189A1 (en) 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027954A2 (fr) * 1997-12-03 1999-06-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HADIDA F ET AL: "CARBOXYL-TERMINAL AND CENTRAL REGIONS OF HUMAN IMMUNODEFICIENCY VIRUS-1 NEF RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES FROM LYMPHOID ORGANS AN IN-VITRO LIMITING DILUTION ANALYSIS", JOURNAL OF CLINICAL INVESTIGATION, vol. 89, no. 1, 1992, pages 53 - 60, XP002406423, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2003040165A3 (en) 2004-06-24
EP1455816A2 (de) 2004-09-15
CA2425648A1 (en) 2002-04-19
AU2001298049A1 (en) 2003-05-19
WO2003040165A2 (en) 2003-05-15
ATE536187T1 (de) 2011-12-15
EP1911461B1 (de) 2011-12-07
AU2001298049A8 (en) 2005-11-03
EP1911461A2 (de) 2008-04-16
EP1911461A3 (de) 2008-07-16

Similar Documents

Publication Publication Date Title
EP1455816A4 (de) Hla-klasse-i- und -ii-bindende peptide und deren verwendung
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
BR9406652A (pt) Composição
ATE342730T1 (de) Hla bindepeptide und ihre verwendungen
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EP1377353A4 (de) Zelltrennungszusammensetzungen und -verfahren
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
EP1089757A4 (de) Hla-bindende peptide und ihre verwendungen.
WO2004007528A3 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
DE69836520D1 (de) Clostridium perfringens Impfstoff
DE60045776D1 (de) Hla-bindungspeptide und ihre anwendungszwecke
DK1230261T3 (da) NY-ESO-1 Nonapeptidderivater og anvendelser af disse
WO2004020592A3 (en) Retroductal salivary gland genetic vaccination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20070226

17Q First examination report despatched

Effective date: 20070529

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMEXA INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071211